SEB Asset Management’s ImmunityBio IBRX Stock Holding History

SEB Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.4M	Hold	2,447,150	–	–	0.08%	212
2026 Q1	$18.8M	Buy	+2,447,150	New	+$16.8M	0.08%	210

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SEB Asset Management's IBRX Position: Q2 2026 in Review

SEB Asset Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 2,447,150 shares worth $21.4M. The position accounts for 0.08% of the portfolio, ranked #212.

SEB Asset Management first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 377 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

SEB Asset Management held 2,447,150 shares of ImmunityBio worth $21.4M as of Q2 2026.
SEB Asset Management left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up 0.08% of SEB Asset Management's portfolio in Q2 2026, its #212 holding.
SEB Asset Management first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
377 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.